name: Insulin^28H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^32H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^36H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Emergency contact information panel:-:Pt:^Emergency contact:-


name: Date and time ED consult request initiated:TmStp:Pt:^Patient:Qn


name: Date and time ED consult starts:TmStp:Pt:^Patient:Qn


name: ED accepting or admitting provider:ID:Pt:Provider:Nom


name: ED accepting or admitting facility:ID:Pt:Facility:Nom


name: Primary care clinic or system:ID:Pt:Facility:Nom


name: Provider who accepted patient in transfer to another facility:ID:Pt:Provider:Nom


name: Individuals accompanying patient to ED:Prid:Pt:^Patient:Nom


name: Time placed into treatment area:TmStp:Pt:^Patient:Qn


name: Problem response to therapy:Find:Pt:^Patient:Nom


name: Problem quality or description:Find:Pt:^Patient:Nom


name: Symptom duration during occurrences or episodes:Time:Pt:^Patient:Qn


name: Limitations in obtaining history:Find:Pt:^Patient:Nom


name: Problem associated signs and symptoms:Find:Pt:^Patient:Nom


name: Viability of current pregnancy:Find:Pt:^Patient:Nar


name: Pain severity verbal numeric scale:Score:Pt:^Patient:Qn


name: Pain severity descriptive category:Arb:Pt:^Patient:Ord


name: Pulse strength on exam:Find:Pt:^Patient:Nar


name: Calculated & derived values:Cmplx:-:^Patient:Set


name: Interpretation and review of laboratory results:Imp:Pt:^Patient:Nom


name: Interpretation and review of laboratory results


name: Care process or plan:Prid:Pt:^Patient:Nom


name: Amount of ED discharge medication to be dispensed:Num:Pt:^Patient:Qn


name: Amount of ED discharge medication to be dispensed


name: Provider assuming ultimate responsibility for care for patient upon ED disposition:ID:Pt:Provider:Nom


name: Provider assuming care for patient upon ED disposition:ID:Pt:Provider:Nom


name: Time accepted for admission or transfer:TmStp:Pt:^Patient:Qn


name: Time received by accepting facility or unit:TmStp:Pt:^Patient:Qn


name: Date and time of ED departure:TmStp:Pt:^Patient:Qn


name: ED follow-up care assistance:Type:Pt:^Patient:Nom


name: Relationship to patient:Type:Pt:^Emergency contact:Nom


name: Onset of painful contractions:TmStp:Pt:^Patient:Qn


name: Continuous ST segment monitoring:Complex:-:^Patient:Set


name: Symptoms & diseases:Hx:Pt:Gynecologic system:Nar


name: Physical findings:Find:Pt:Brain stem reflexes:Nar


name: Serology & blood bank studies:Complex:-:^Patient:Set


name: Mixed venous oxygen saturation monitoring:Cmplx:-:^Patient:Set


name: Mixed venous oxygen saturation monitoring


name: TCRB gene+TCRD gene+TCRG gene rearrangements:Arb:Pt:Bld/Tiss:Ord:Molgen


name: Parietaria judaica recombinant (rPar j) 2 Ab.IgE:ACnc:Pt:Ser:Qn


name: BCHE gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Cells.terminal deoxyribonucleotidyl transferase/Cells:NFr:Pt:CSF:Qn:Flow cytometry


name: Chlamydia sp Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Chlamydia sp Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Coxiella burnetii Ab.IgM^2nd specimen:ACnc:Pt:Ser:Qn:IF


name: Coxiella burnetii Ab.IgM^1st specimen:Titr:Pt:Ser:SemiQn:IF


name: Coxiella burnetii Ab.IgG^2nd specimen:Titr:Pt:Ser:SemiQn:IF


name: Coxiella burnetii Ab.IgG^1st specimen:Titr:Pt:Ser:SemiQn:IF


name: Fractional excretion of phosphate:Ratio:24H:Urine+Ser/Plas:Qn


name: Hepatitis C virus c1 Ab:PrThr:Pt:Ser:Ord:IB


name: Hepatitis C virus c2 Ab:PrThr:Pt:Ser:Ord:IB


name: Hepatitis C virus E2 Ab:PrThr:Pt:Ser:Ord:IB


name: Hepatitis C virus NS3 Ab:PrThr:Pt:Ser:Ord:IB


name: Hepatitis C virus NS4 Ab:PrThr:Pt:Ser:Ord:IB


name: Hydrogen/Expired gas^pre dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^1H post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^2H post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^2.5H post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^3.5H post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^1.5H post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^30M post dose glucose:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^30M post dose lactulose:VFr:Pt:Exhl gas:Qn


name: Insulin^8H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^64H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^68H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^3D post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^56H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^2D post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^60H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^44H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Insulin^40H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Mycoplasma pneumoniae Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Neuronal nuclear type 2 Ab:PrThr:Pt:CSF:Ord:IF


name: Protein fractions.oligoclonal bands:Imp:Pt:Ser/Plas:Nom:Isoelectric focusing


name: Renin^upright+30M post XXX challenge:MCnc:Pt:Plas:Qn


name: Renin^upright+1H post XXX challenge:MCnc:Pt:Plas:Qn


name: Rheumatoid arthritis nuclear Ab:Titr:Pt:Ser:SemiQn:IF


name: Taenia solium larva Ab:PrThr:Pt:Ser:Ord:IA


name: 11-Deoxycortisol^4D post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^4H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Hepatitis C virus Ab.IgG:ACnc:Pt:Ser:Qn:IA


name: Insulin^52H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Legionella pneumophila Ab.IgG^1st specimen:Titr:Pt:Ser:SemiQn:IF


name: Mycoplasma pneumoniae Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Chromosome 12 aneuploidy:Find:Pt:Amnio fld/CVS:Nom:FISH


name: Deprecated Outcome and assessment information set (OASIS) form - version C


name: Outcome and assessment information set (OASIS) form - version C


name: Clinical record items:-:RptPeriod:^Patient:-:CMS Assessment


name: Patient history and diagnoses:-:Pt:^Patient:-


name: Neuro & emotional & behavioral status - start of care or resumption of care:-:-:^Patient:-


name: Therapy need and plan of care:-:RptPeriod:^Patient:-:CMS Assessment


name: Data items collected at inpatient facility admission or agency discharge only:-:Pt:^Patient:-


name: Labor and delivery admission history and physical note:Find:Pt:{Setting}:Doc:{Role}


name: Labor and delivery admission history and physical note


name: Labor and delivery summary note:Find:Pt:{Setting}:Doc:{Role}


name: Deprecated Maternal discharge summary note


name: Pregnancy visit summary note:Find:Pt:^Patient:Nar


name: Delivery date:Date:Pt:^Patient:Qn:Estimated from quickening date


name: Delivery date:Date:Pt:^Patient:Qn:Estimated from date fundal height reaches umb


name: Date fundal height reaches umbilicus:Date:Pt:^Patient:Qn


name: Body weight:Mass:Pt:^Fetus:Qn:Estimated by palpation


name: Date next clinic visit:Date:Pt:^Patient:Qn


name: Labor and delivery process:Find:Pt:^Patient:Nar


name: Newborn status at maternal discharge:Find:Pt:^Newborn:Nar


name: Antenatal testing and surveillance:Find:Pt:^Patient:Nar


name: Anesthesia risk review of systems:Find:Pt:^Patient:Nar


name: Fatty acid oxidation newborn screen panel:-:Pt:Bld.dot:-


name: Fatty acid oxidation newborn screen panel


name: Organic acid newborn screen panel:-:Pt:Bld.dot:-


name: Congenital adrenal hyperplasia newborn screening panel:-:Pt:Bld.dot:-


name: Congenital adrenal hyperplasia newborn screening panel


name: Biotinidase newborn screening panel:-:Pt:Bld.dot:-


name: Eosinophil cationic protein:MCnc:Pt:Nasal fluid:Qn


name: Cyclic citrullinated peptide Ab.IgA+IgG:ACnc:Pt:Ser/Plas:Qn:IA


name: Phenol^^adjusted to specific gravity 1.024:MCnc:Pt:Urine:Qn


name: Follitropin^10M pre dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Follitropin^1.5H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Follitropin^1H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Follitropin^30M post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Follitropin^20M post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^2H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^1.5H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^1H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^30M post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^20M post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^10M pre dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Macular grid.center point thickness:Len:Pt:Eye:Qn:OCT


name: Macular grid.center subfield thickness:Len:Pt:Eye:Qn:OCT


name: Macular grid.inner superior subfield thickness:Len:Pt:Eye:Qn:OCT


name: Macular grid.inner nasal subfield thickness:Len:Pt:Eye:Qn:OCT


name: Macular grid.inner inferior subfield thickness:Len:Pt:Eye:Qn:OCT


name: Macular grid.inner temporal subfield thickness:Len:Pt:Eye:Qn:OCT


name: Type of client:Type:Pt:{Nursing unit}:Nom:NMMDS


name: Type of encounter:Type:Pt:{Nursing unit}:Nom:NMMDS


name: Volume of nursing delivery unit or service panel:-:Pt:{Nursing unit}:-:NMMDS


name: Volume of nursing delivery unit or service panel


name: Method of care delivery:Type:Pt:{Nursing unit}:Nom:NMMDS


name: Newborn Screening Report summary panel:-:Pt:^Patient:-


name: Unhealed pressure injury at Stage 2 or higher or designated as unstageable:Find:Pt:^Patient:Nom:OASIS-C


name: CYP11B1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: PRNP gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: SRY gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: CYP11B1 gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: PRNP gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: SRY gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Chromosome 13+18+21+X+Y aneuploidy:Find:Pt:Amnio fld/CVS:Nom:FISH


name: Risk for hospitalization:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: 11-Ketoetiocholanolone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Ketoetiocholanolone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Ketoetiocholanolone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Deoxycorticosterone^pre 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Toxoplasma gondii Ab.IgG & IgM panel:-:Pt:Ser:Qn


name: Metanephrine.free & Normetanephrine.free panel:SCnc:Pt:Ser/Plas:Qn


name: Metanephrine.free & Normetanephrine.free panel


name: Colorado tick fever virus Ab.IgG & IgM:Imp:Pt:Ser:Nar


name: Colorado tick fever virus Ab.IgG & IgM panel:Titr:Pt:Ser:SemiQn


name: Valproate.free & Valproate panel:-:Pt:Ser/Plas:Qn


name: Gliadin peptide Ab.IgA & IgG panel:-:Pt:Ser:-


name: Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion


name: Glucose-6-Phosphate dehydrogenase newborn screen panel:-:Pt:Bld.dot:-


name: Glucose-6-Phosphate dehydrogenase newborn screen panel


name: Acylcarnitine newborn screen panel:-:Pt:Bld.dot:-


name: Acylcarnitine newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Acylcarnitine newborn screening comment-discussion


name: Number of pressure ulcers present upon admission &or reentry - unstageable due to non-removable dressing:Num:Pt:^Patient:Qn:OASIS-C


name: Number of pressure ulcers present upon admission &or reentry - unstageable due to coverage of wound bed by slough &or eschar:Num:Pt:^Patient:Qn:OASIS-C


name: Number of pressure ulcers present upon admission &or reentry - unstageable with suspected deep tissue injury in evolution:Num:Pt:^Patient:Qn:OASIS-C


name: Full newborn screening summary report for display or printing:-:Pt:^Patient:Doc


name: Full newborn screening summary report for display or printing


name: Newborn screening report - overall interpretation:Imp:Pt:^Patient:Nom


name: Newborn conditions with positive markers:Prid:Pt:Bld.dot:Nom


name: Referral note:Find:Pt:{Setting}:Doc:Thoracic and cardiac surgery


name: Referral note:Find:Pt:{Setting}:Doc:Nutrition and dietetics


name: Referral note:Find:Pt:{Setting}:Doc:Oral and maxillofacial surgery


name: Pyruvate^5M post XXX challenge:MCnc:Pt:Bld:Qn


name: 18-Hydroxycorticosterone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 18-Hydroxycorticosterone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Hearing loss newborn screening comment-discussion:Txt:Pt:Ear:Nar


name: Hearing loss newborn screening comment-discussion


name: Infectious diseases newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Infectious diseases newborn screening comment-discussion


name: Hemoglobin disorders newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Hemoglobin disorders newborn screening comment-discussion


name: Galactosemias newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Galactosemias newborn screening comment-discussion


name: Congenital hypothyroidism newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Congenital adrenal hyperplasia newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Congenital adrenal hyperplasia newborn screening comment-discussion


name: Cystic fibrosis newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Cystic fibrosis newborn screening comment-discussion


name: Organic acidemias defects newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Organic acidemias defects newborn screening comment-discussion


name: Fatty acid oxidation defects newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Fatty acid oxidation defects newborn screening comment-discussion


name: Amino acidemias newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Amino acidemias newborn screening comment-discussion


name: Unique bar code number:ID:Pt:Initial sample:Nom


name: Highest level of education:Hx:Pt:^Mother:Ord


name: Referral note:Find:Pt:{Setting}:Doc:Critical Care Medicine


name: Referral note:Find:Pt:{Setting}:Doc:Obstetrics and Gynecology


name: Lupus anticoagulant neutralization.dilute phospholipid/Lupus anticoagulant neutralization.high phospholipid:Ratio:Pt:PPP:Qn:Coag


name: Lupus anticoagulant neutralization.dilute phospholipid/Lupus anticoagulant neutralization.high phospholipid


name: Inpatient procedure relevant to plan of care:-:Pt:^Patient:-


name: Inpatient procedure relevant to plan of care


name: Current number of unhealed pressure ulcers:-:Pt:^Patient:-


name: Number of pressure injuries at each stage:-:Pt:^Patient:Set


name: Number of pressure injuries present at admission:-:Pt:^Patient:Set


name: Stage 3 or 4 pressure injury with largest surface dimensions:-:Pt:^Patient:-


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Start of care


name: Outcome and assessment information set (OASIS) form - version C - Start of care


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Resumption of Care


name: Outcome and assessment information set (OASIS) form - version C - Resumption of Care


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Follow-Up


name: Outcome and assessment information set (OASIS) form - version C - Follow-Up


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Transfer to facility


name: Outcome and assessment information set (OASIS) form - version C - Transfer to facility


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Discharge from agency


name: Outcome and assessment information set (OASIS) form - version C - Discharge from agency


name: Patient &or caregiver drug education intervention:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Patient &or caregiver drug education intervention


name: Prior medication management:-:RptPeriod:^Patient:-:CMS Assessment


name: Plan of care synopsis:-:RptPeriod:^Patient:-:CMS Assessment


name: Current payment sources for home care:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Reason for assessment:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Date of Physician-ordered Start of Care (Resumption of Care):Date:RptPeriod:^Patient:Qn:CMS Assessment


name: Inpatient discharge facility within the past 14D:Type:14D:^Patient:Nom:CMS Assessment


name: Inpatient stay within last 14D - ICD code:Prid:14D:^Patient:Nom:OASIS-C


name: Frequency of pain interfering with activity or movement:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Pressure injury assessment was conducted:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Oldest non-epithelialized stage 2 pressure injury present at discharge:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Diameter.long:Len:Pt:Pressure injury.largest stage 3 or 4:Qn:OASIS-C


name: Depth:Len:RptPeriod:Pressure injury.largest stage 3 or 4:Qn:CMS Assessment


name: Status of most problematic pressure injury:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Stage of most problematic pressure injury:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Stasis pressure injury:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Number of stasis ulcers:Num:RptPeriod:^Patient:Ord:CMS Assessment


name: Status of most problematic stasis pressure injury:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Status of most problematic surgical wound:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Exertion level causing shortness of breath:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Respiratory treatments administered at home:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Symptoms in heart failure patients:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Heart failure follow-up:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: When urinary incontinence occurs:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Standardized depression screening was conducted:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Bathing - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Toilet transferring - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Toileting hygiene - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Transferring - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Locomotion - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Feeding - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Prepare light meals - functional ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Standardized fall risk assessment was conducted:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Drug regimen review identified potential medication issues:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Medication intervention since admission &or reentry:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Patient &or caregiver received high risk drug education:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Patient &or caregiver received high risk drug education


name: Oral medication management - prior ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Injectable medication management - prior ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with ADL:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with IADL:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with medication administration:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with medical procedures &or treatments:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with management of equipment:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with supervision and safety:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-agency caregiver ability and willingness to assist with advocacy or facilitation of patient participation:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Advocacy or facilitation of patient participation


name: ADL or IADL assistance frequency from any caregiver:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes patient-specific parameters for notifying physician of changes:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes diabetic foot care:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes fall prevention interventions:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes depression intervention:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes intervention to monitor and mitigate pain:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Intervention to monitor and mitigate pain


name: Plan of care includes intervention to prevent pressure injuries:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Plan of care includes pressure injury treatment - moist healing:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Emergent care utilized:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Reason for emergent care:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Deprecated Discharge disposition [CMS Assessment]


name: Reason for hospitalization:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Risk of developing pressure injuries:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Patient &or caregiver drug education intervention:Find:Pt:^Patient:Ord:OASIS-C


name: Management of injectable medications - ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Management of oral medications - ability:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Types and sources of assistance:-:RptPeriod:^Patient:-:CMS Assessment


name: Herpes simplex virus 2 Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Varicella zoster virus Ab.IgM^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Beta hydroxybutyrate^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Glucose^1M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Insulin^5M post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Lactate^1M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^10M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^2H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^3H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^20M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^3M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^30M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^5M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^1.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Albumin:MCnc:12H:Urine:Qn:Detection limit <= 20 mg/L


name: Cells.CD3+TCR alpha beta+/Cells:NFr:Pt:Body fld:Qn


name: Cells.CD3+TCR gamma delta+/Cells:NFr:Pt:Body fld:Qn


name: Liver kidney microsomal 1 Ab:Titr:Pt:Ser:SemiQn:IF


name: Muscle specific receptor tyrosine kinase Ab:ACnc:Pt:Ser:Qn:IA


name: Cells.terminal deoxyribonucleotidyl transferase:PrThr:Pt:Body fld:Ord


name: Toxoplasma gondii DNA:PrThr:Pt:Body fld:Ord:Probe.amp.tar


name: Deprecated Nuclear Ab [Titer] in Synovial fluid by Immunofluorescence


name: Nuclear Ab pattern:Imp:Pt:Synv fld:Nom:IF


name: Tubular basement membrane Ab:ACnc:Pt:Ser:Qn


name: Deprecated Soluble liver Ab [Presence] in Serum by Immunoassay


name: Chromosome 18 aneuploidy:Find:Pt:Amnio fld/CVS:Nom:FISH


name: Chromosome 13 aneuploidy:Find:Pt:Amnio fld/CVS:Nom:FISH


name: Deprecated Outcome and assessment information set (OASIS) form - version C - Death at home


name: Outcome and assessment information set (OASIS) form - version C - Death at home


name: Calcitriol^2H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: Calcitriol^2H post dose calcium:MCnc:Pt:Ser/Plas:Qn


name: Calcitriol^3H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: Calcitriol^3H post dose calcium:MCnc:Pt:Ser/Plas:Qn


name: Calcitriol^1H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: Calcitriol^1H post dose calcium:MCnc:Pt:Ser/Plas:Qn


name: 11-Ketoandrosterone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Ketoandrosterone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Ketoandrosterone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Ketoandrosterone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Ketoandrosterone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Ketoandrosterone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Ketoetiocholanolone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Ketoetiocholanolone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Ketoetiocholanolone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Deoxycorticosterone^30M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycorticosterone^1H post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1D post dose dexamethasone:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^2D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^2D post dose dexamethasone:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1D post dose metyraPONE:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1D post dose metyraPONE:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^2D post dose metyraPONE:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^2D post dose metyraPONE:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^pre 250 ug corticotropin:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^45M post 250 ug corticotropin:MCnc:Pt:Ser/Plas:Qn


name: 11-Hydroxyandrosterone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyandrosterone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Hydroxyandrosterone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyandrosterone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Hydroxyandrosterone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyandrosterone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 11-Hydroxyetiocholanolone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Ketogenic steroids^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Ketogenic steroids^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Hydroxypregnenolone^1D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxypregnenolone^2D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^10th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^11th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^12th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^8th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^9th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^1st specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^2nd specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^3rd specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^4th specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^5th specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^6th specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^7th specimen post dose gonadotropin releasing hormone:MCnc:Pt:Ser/Plas:Qn


name: 18-Hydroxycortisol^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 18-Hydroxycortisol^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycorticosterone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycorticosterone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^1D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^2D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: Calcidiol^2H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: Calcidiol^3H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: Calcidiol^1H post dose calcium:SCnc:Pt:Ser/Plas:Qn


name: 3-Alpha-Androstanediol glucuronide^pre dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 3-Alpha-Androstanediol glucuronide^1D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: Alpha cortolone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortolone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortolone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortolone^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortolone^pre dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortolone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortolone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: Androsterone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: Androsterone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: Other error requiring modification:Type:Pt:^Patient:Ord:MDSv3


name: Other error requiring modification.other specified:Type:Pt:^Patient:Nom:MDSv3


name: Reasons for inactivation - event did not occur:Find:Pt:^Patient:Ord:MDSv3


name: Other error requiring error requiring inactivation:Find:Pt:^Patient:Ord:MDSv3


name: Other error requiring error requiring inactivation.other specified:Find:Pt:^Patient:Nom:MDSv3


name: Medicare non-therapy Part A HIPPS code:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Medicare non-therapy Part A - RUG version code:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Medicare non-therapy Part A - RUG version code


name: Alternate state Medicaid billing - RUG group:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Alternate state Medicaid billing - RUG version code:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Alternate state Medicaid billing - RUG version code


name: One or more unhealed pressure injuries stage 1 or higher:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Speech-language pathology and audiology services - individual minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Occupational therapy - individual minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Physical therapy - individual minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Participation in assessment:Find:RptPeriod:^Guardian or legally authorized representative:Nom:CMS Assessment


name: Items from most recent prior OBRA or scheduled PPS assessment:-:Pt:^Patient:-


name: Items from most recent prior OBRA or scheduled PPS assessment


name: Visual function - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Visual function - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Infection of the foot:Find:Pt:^Patient:Ord:MDSv3


name: 3-Alpha-Androstanediol glucuronide^2D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 3-Alpha-Androstanediol glucuronide^pre dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 3-Alpha-Androstanediol glucuronide^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 3-Alpha-Androstanediol glucuronide^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Androstanolone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Androstanolone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^post 25 mg captopril PO:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^pre 25 mg captopril PO:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^2H post 25 mg captopril PO:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^3H post 25 mg captopril PO:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^3H post 25 mg captopril PO:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^1H post 25 mg captopril PO:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^2H post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^15M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^15M post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^3H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^3H post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^30M post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^1H post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^pre 250 ug corticotropin IM:MCnc:Pt:Ser/Plas:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre dose dexamethasone:MRat:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^pre dose dexamethasone:MRat:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: 5-Alpha tetrahydrocortisol^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortol^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortol^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortol^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortol^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortol^pre dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortol^pre dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortol^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: Alpha cortol^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: Alpha cortolone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: Newborn screening test results panel:-:Pt:Bld.dot:-


name: Progesterone^20M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Number of occult blood specimens recommended by testing kit protocol:Num:Pt:Stool:Qn


name: HEDIS 2010 Tests used in early prenatal care - ABO & Rh (PPC-C):-:Pt:^Patient:-


name: HEDIS 2010 Tests used in early prenatal care - ABO & Rh (PPC-C)


name: HEDIS 2010-2013 Tests used in early prenatal care - Rubella (PPC-C):-:Pt:^Patient:-


name: Androsterone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: Androsterone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: Androsterone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: Androsterone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: C peptide^190M post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: C peptide^3.3H post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: C peptide^1.3H post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Humidifier heated wire temperature differential setting:Temp:Pt:Ventilator airway circuit:Qn


name: Tidal volume.spontaneous min setting:Vol:Pt:Ventilator.alarm:Qn


name: Tidal volume.inspired max setting:Vol:Pt:Ventilator.alarm:Qn


name: Tidal volume.exhaled max setting:Vol:Pt:Ventilator.alarm:Qn


name: Tubular basement membrane Ab:Titr:Pt:Ser:SemiQn:IF


name: U1 small nuclear ribonucleoprotein Ab:ACnc:Pt:Ser:Qn:IA


name: Protein fractions.oligoclonal bands.IgG:PrThr:Pt:Ser/Plas:Ord:Isoelectric focusing


name: Protein fractions.oligoclonal bands.IgM:PrThr:Pt:Ser/Plas:Ord:Isoelectric focusing


name: Coxiella burnetii Ab.IgM^2nd specimen:PrThr:Pt:Ser:Ord:IF


name: Legionella pneumophila Ab.IgG^1st specimen:PrThr:Pt:Ser:Ord:IF


name: Legionella pneumophila Ab.IgG^2nd specimen:PrThr:Pt:Ser:Ord:IF


name: Mycoplasma pneumoniae Ab.IgG^1st specimen:PrThr:Pt:Ser:Ord:IA


name: Mycoplasma pneumoniae Ab.IgG^2nd specimen:PrThr:Pt:Ser:Ord:IA


name: Chlamydia sp Ab.IgG^1st specimen:PrThr:Pt:Ser:Ord:IA


name: Chlamydia sp Ab.IgG^2nd specimen:PrThr:Pt:Ser:Ord:IA


name: Coxiella burnetii Ab.IgG^1st specimen:PrThr:Pt:Ser:Ord:IF


name: Coxiella burnetii Ab.IgG^2nd specimen:PrThr:Pt:Ser:Ord:IF


name: Lipid panel with direct LDL:-:Pt:Ser/Plas:Qn


name: Biotinidase deficiency newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar


name: Biotinidase deficiency newborn screening comment-discussion


name: Infant factors that affect newborn screening interpretation:Find:Pt:^Patient:Nom


name: Obstetric estimation of gestational age:Time:Pt:^Patient:Qn


name: State printed on filter paper card:ID:Pt:NBS card:Nom


name: Newborn screen card data panel:-:Pt:Bld.dot:-


name: Conditions tested for in this newborn screening study:ID:Pt:Bld.dot:Nom


name: Conditions tested for in this newborn screening study


name: Newborn conditions with equivocal markers:Prid:Pt:Bld.dot:Nom


name: Unique bar code number:ID:Pt:Current sample:Nom


name: Newborn screening short narrative summary:Txt:Pt:^Patient:Nar


name: Newborn screening short narrative summary


name: Corticotropin^20M post XXX challenge:MCnc:Pt:Plas:Qn


name: Lactate^40M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Lactate^6M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Basement membrane zone BP180 Ab:ACnc:Pt:Ser:Qn:IA


name: IKBKG gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: TNFRSF13B gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: WAS gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Procollagen type III.N-terminal propeptide:ACnc:Pt:Ser:Qn


name: IKBKG gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen


name: TNFRSF13B gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: WAS gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Coagulation factor XIII inhibitor:PrThr:Pt:PPP:Ord:Coag


name: Platelet factor 4 heparin complex induced Ab:PrThr:Pt:Ser/Plas:Ord:IA


name: Coagulation surface induced.factor substitution^immediately after addition of normal plasma/Coagulation surface induced:TRto:Pt:PPP:Qn:Coag


name: Histoplasma capsulatum Ag:MCnc:Pt:Body fld:Qn


name: Trimipramine & Nortrimipramine panel:-:Pt:Ser/Plas:Qn


name: Campylobacter jejuni+Campylobacter coli Ag:PrThr:Pt:Stool:Ord


name: Salmonella typhi O Vi Ab:PrThr:Pt:Ser:Ord


name: Myeloperoxidase Ab & Proteinase 3 panel:-:Pt:Ser:Qn


name: Immunoglobulin light chains.free panel:-:Pt:Ser:Qn


name: Thyroglobulin & Thyroglobulin Ab panel:-:Pt:Ser/Plas:Qn


name: Thyroglobulin & Thyroglobulin Antibody panel


name: Complete blood count W Ordered Manual Differential panel:-:Pt:Bld:Qn


name: Complete blood count W Ordered Manual Differential panel


name: Dehydroepiandrosterone^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: Dehydroepiandrosterone^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: Dehydroepiandrosterone^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: Dehydroepiandrosterone^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: Dehydroepiandrosterone^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: Dehydroepiandrosterone^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: Organic acidemia conditions suspected:Prid:Pt:Bld.dot:Nom


name: Fatty acid oxidation conditions suspected:Prid:Pt:Bld.dot:Nom


name: Amino acidemia disorder suspected:Prid:Pt:Bld.dot:Nom


name: HEDIS 2010 Tests used in early prenatal care (PPC-C):-:Pt:^Patient:-


name: HEDIS 2010 Tests used in early prenatal care (PPC-C)


name: HEDIS 2010-2013 Codes to identify anticonvulsant serum concentration monitoring tests - carBAMazepine (MPM-E):-:Pt:^Patient:-


name: HEDIS 2010, 2011 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E):-:Pt:^Patient:-


name: HEDIS 2010, 2011 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A):-:Pt:^Patient:-


name: HEDIS 2010,2011 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify physiologic monitoring tests (MPM-A):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify physiologic monitoring tests (MPM-A)


name: HEDIS 2010 Codes to identify evidence of nephropathy (CDC-K):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify evidence of nephropathy (CDC-K)


name: HEDIS 2010 Codes to identify nephropathy screening tests (CDC-J):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify nephropathy screening tests (CDC-J)


name: HEDIS 2010 Codes to identify LDLc screening (CDC-H):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify LDLc screening (CDC-H)


name: HEDIS 2010 Codes to identify LDLc screening (CMC-D):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify LDLc screening (CMC-D)


name: HEDIS 2010-2013 Codes to identify Chlamydia screening (CHL-C):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify sexually active women (CHL-B):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify sexually active women (CHL-B)


name: HEDIS 2010 Codes to identify colorectal cancer screening (COL-A):-:Pt:^Patient:-


name: HEDIS 2010 Codes to identify colorectal cancer screening (COL-A)


name: Prescription for medical equipment or product:Find:Pt:{Setting}:Doc:{Role}


name: Prescription for medical equipment or product


name: Prescription for diagnostic or specialist care:Find:Pt:{Setting}:Doc:{Role}


name: Prescription for diagnostic or specialist care


name: Coagulation dilute Russell viper venom induced.excess phospholipid:Time:Pt:PPP:Qn


name: Activated clotting time.kaolin induced:Time:Pt:PPP^Control:Qn:Coag


name: Snowshoe hare virus Ab.IgG:PrThr:Pt:Ser:Ord:IA


name: Thyrotropin^5M post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Cucumis melo cantalupensis basophil bound Ab:ACnc:Pt:Bld:Qn:LHR


name: Cucumis melo cantalupensis Ab.IgG4:MCnc:Pt:Ser:Qn


name: Cucumis melo cantalupensis Ab.IgG.RAST class


name: Cucumis melo spp Ab.IgG.RAST class:PrThr:Pt:Ser:Ord


name: Cucumis melo cantalupensis Ab.IgG:ACnc:Pt:Ser:Qn


name: Cucumis melo cantalupensis Ab.IgE.RAST class


name: Cucumis melo cantalupensis Ab.IgE:ACnc:Pt:Ser:Qn


name: Cucumis melo spp basophil bound Ab:ACnc:Pt:Bld:Qn:LHR


name: Pregnanediol^pre high dose dexamethasone:MCnc:24H:Urine:Qn


name: Pregnanediol^pre high dose dexamethasone:MRat:24H:Urine:Qn


name: Pregnanediol^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: Pregnanediol^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: Pregnanediol^2D post dose dexamethasone:MCnc:24H:Urine:Qn


name: Pregnanediol^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: C peptide^100M post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Influenza virus A H1.neuraminidase inhibitor resistance:Susc:Pt:XXX:Ord:Genotyping


name: Influenza virus A 2009 H1N1v.neuraminidase inhibitor resistance:Susc:Pt:XXX:Ord:Genotyping


name: Influenza virus A+B.neuraminidase inhibitor resistance:Susc:Pt:XXX:Ord:Genotyping


name: Clostridioides difficile glutamate dehydrogenase:PrThr:Pt:Stool:Ord


name: C. difficile Glutamate Dehydrogenase Measurement


name: B little g super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: B little g super little a Ab:Titr:Pt:Ser/Plas:SemiQn


name: B little g super little a Ag:PrThr:Pt:RBC:Ord


name: AIRE gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: ADNFLE gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Basement membrane zone BP230 Ab:ACnc:Pt:Ser/Plas:Qn


name: Borrelia burgdorferi C6 Ab:PrThr:Pt:Ser:Ord


name: CACNA1S+SCN4A gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: CDKN2A+CDK4 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: CFTR+PRSS1+SPINK1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Coccidioides immitis Ab.IgG:PrThr:Pt:CSF:Ord:Comp fix


name: CPVT1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: DPYD2A gene targeted mutation analysis:Arb:Pt:Bld/Tiss:Ord:Molgen


name: FECH gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: FLCN gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Glucose^3H post 75 g glucose PO:MCnc:Pt:Urine:Qn


name: Glucose^4th specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn


name: Glucose^5th specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn


name: IDUA gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Influenza virus A H2 RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Insulin-like growth factor^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: KRIT1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Legionella pneumophila 1+3+4+5+6+8 Ab:PrThr:Pt:Ser:Ord


name: MSH2 gene+MLH1 gene+MSH6 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: PKD2 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: HLA-B SBT:Type:Pt:Bone mar:Nom:High resolution


name: RYR1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: SCN4A gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Inpatient procedure relevant to plan of care:Type:Pt:^Patient:Nom:OASIS-C


name: Date pressure injury first identified:Date:RptPeriod:Pressure injury.oldest non-epithelialized stage 2:Qn:CMS Assessment


name: C little h super little a Ag:PrThr:Pt:RBC:Ord


name: C little h super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: C little o super little a Ag:PrThr:Pt:RBC:Ord


name: C little o super little b Ag:PrThr:Pt:RBC:Ord


name: C little s super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: C little s super little a Ag:PrThr:Pt:Ser/Plas:Ord


name: D little o super little b Ab:PrThr:Pt:Ser/Plas:Ord


name: D little o super little b Ag:PrThr:Pt:RBC:Ord


name: G little o super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: I little n super little b Ag:PrThr:Pt:RBC:Ord


name: I little n super little b Ab:PrThr:Pt:Ser/Plas:Ord


name: J little r super little a Ag:PrThr:Pt:RBC:Ord


name: J little r super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: K little n super little a Ag:PrThr:Pt:RBC:Ord


name: K little n super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: K little n super little b Ab:PrThr:Pt:Ser/Plas:Ord


name: K little n super little b Ag:PrThr:Pt:RBC:Ord


name: M little c C super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: R little g super little a Ag:PrThr:Pt:RBC:Ord


name: R little g super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: W little r super little a Ag:PrThr:Pt:RBC:Ord


name: W little r super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: Y little k super little a Ag:PrThr:Pt:RBC:Ord


name: Y little k super little a Ab:PrThr:Pt:Ser/Plas:Ord


name: Urinalysis complete W Reflex Culture panel:-:Pt:Urine:-


name: Urinalysis complete W Reflex Culture panel


name: Current number of unhealed (non-epithelialized) pressure injuries at each stage:-:Pt:^Patient:-:OASIS-C


name: When confused within the last 14D:Find:14D:^Patient:Ord:CMS Assessment


name: Current payment sources for home care.other specified:Find:Pt:^Patient:Nom:OASIS-C


name: Inpatient discharge facility.other specified:Type:Pt:^Patient:Nom:OASIS-C


name: Swing bed clinical change assessment:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Entry &or discharge reporting:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Multidrug-resistant organism (MDRO) in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Wound infection (other than foot) in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Neurogenic bladder in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Obstructive uropathy in the last 7D:Find:7D:^Patient:Ord:MDSv3


name: Huntington's disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Tourette's syndrome in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Psychotic disorder (other than schizophrenia) in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Respiratory failure in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Staff pain assessment interview should be conducted:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Frequency of indicator of pain or possible pain:NRat:RptPeriod:^Patient:Ord:CMS Assessment


name: Frequency of indicator of pain or possible pain


name: Unable to examine oral or dental status:Find:Pt:^Patient:Ord:MDSv3


name: Patient health questionnaire 2 item:-:2W:^Patient:-:PHQ.CMS


name: Prior Functioning ADL and IADL:-:RptPeriod:^Patient:-:CMS Assessment


name: Resident has one or more unhealed pressure injuries at stage 1 or higher:Find:Pt:^Patient:Ord:MDSv3


name: Date of oldest stage 2 pressure injury:Date:RptPeriod:Pressure injury.oldest non-epithelialized stage 2:Qn:CMS Assessment


name: Other open lesion(s) on the foot:Find:Pt:^Patient:Ord:MDSv3


name: Number of D injection of any type were received in last 5D or since admission &or reentry if less than 7D:Num:7D:^Patient:Qn:MDSv3


name: Number of D insulin injections were received in last 7D or since admission &or reentry if less than 7D:NRat:7D:^Patient:Qn:CMS Assessment


name: Number of D insulin injections were received in last 7D or since admission &or reentry if less than 7D


name: Number of D the physician changed the resident's insulin orders in last 7D or since admission &or reentry if less than 7D:NRat:7D:^Patient:Qn:CMS Assessment


name: Antibiotic received in last 7D or since admission &or reentry if less than 7D:Find:7D:^Patient:Ord:MDSv3


name: Diuretic received in last 7D or since admission &or reentry if less than 7D:Find:7D:^Patient:Ord:MDSv3


name: Date of influenza vaccination:Date:Pt:^Patient:Qn


name: Speech-language pathology and audiology services:-:Pt:^Patient:-:MDSv3


name: Speech-language pathology and audiology services


name: Speech-language pathology and audiology services - concurrent minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Speech-language pathology and audiology services - group minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Occupational therapy - concurrent minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Occupational therapy - group minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Physical therapy - concurrent minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Physical therapy - group minutes in the last 7D:Time:7D:^Patient:Qn:CMS Assessment


name: Resident's overall goal established during assessment process:Find:Pt:^Patient:Nom:MDSv3


name: Information source for overall goal:Find:Pt:^Patient:Nom:MDSv3


name: Active discharge planning in place for resident return to community:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Determination made by resident and core planning team regarding discharge to community:Find:Pt:^Patient:Nom:MDSv3


name: Resident has been asked about returning to the community:Find:Pt:^Patient:Nom:MDSv3


name: Wants to talk to someone about the possibility of returning to the community:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Referral has been made to the local contact agency:Find:RptPeriod:^Patient:Nom:CMS Assessment


name: Prior assessment brief interview for mental status summary score:Score:Pt:^Patient:Qn:MDSv3


name: Prior assessment resident mood interview (PHQ-9) total severity score:Score:Pt:^Patient:Qn:MDSv3


name: Prior assessment staff assessment of resident mood interview (PHQ-9) total severity score:Score:Pt:^Patient:Qn:MDSv3


name: Care Area Assessment (CAA) Summary:-:Pt:^Patient:-:MDSv3


name: Care Area Assessment (CAA) and care planning:-:Pt:^Patient:-:MDSv3


name: Care Area Assessment (CAA) and care planning


name: Care Area Assessment (CAA) results:-:Pt:^Patient:-:MDSv3


name: Delirium - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Delirium - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Cognitive loss &or dementia - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Cognitive loss &or dementia - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Communication - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Communication - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: ADL functional &or rehabilitation potential - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: ADL functional &or rehabilitation potential - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Urinary incontinence and indwelling catheter - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Urinary incontinence and indwelling catheter - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Psychosocial well being - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Psychosocial well being - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Mood state - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Mood state - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Behavioral symptoms - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Behavioral symptoms - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Activities - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Activities - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Falls - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Falls - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Nutritional status - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Nutritional status - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Feeding tube - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Feeding tube - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Dehydration &or fluid maintenance - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Dehydration &or fluid maintenance - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Dental care - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Dental care - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Pressure injury - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Pressure injury - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Psychotropic drug use - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Psychotropic drug use - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Physical restraints - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Physical restraints - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Pain - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Pain - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Return to community referral - care area triggered:Find:Pt:^Patient:Ord:MDSv3


name: Return to community referral - addressed in care plan:Find:Pt:^Patient:Ord:MDSv3


name: Date of Care Area Assessment (CAA) information:Date:Pt:^Patient:Qn:MDSv3


name: Date of Care Area Assessment (CAA) information


name: Location of Care Area Assessment (CAA) information:Find:Pt:^Patient:Ord:MDSv3


name: Type of record:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Saccharomyces cerevisiae Ab.IgG.RAST class


name: 10 minutes pre dose gonadotropin releasing hormone


name: 1st specimen post dose gonadotropin releasing hormone


name: 20 minutes post dose gonadotropin releasing hormone


name: 2nd specimen post dose gonadotropin releasing hormone


name: 3rd specimen post dose gonadotropin releasing hormone


name: 4th specimen post dose gonadotropin releasing hormone


name: 5th specimen post dose gonadotropin releasing hormone


name: 6th specimen post dose gonadotropin releasing hormone


name: 7th specimen post dose gonadotropin releasing hormone


name: immediately after 1:2 addition of platelet lysate


name: immediately after 1:2 addition of saline


name: Consensus Measures for Phenotypes and Exposures (PhenX)


name: Hemogram WO Platelets & W Manual Differential panel


name: Complete blood count WO Differential panel


name: MDS supplemental items section - version 2.0


name: MDS quarterly assessment form - version 2.0 - optional version for RUG-III


name: MDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 update


name: Flunitrazepam & 7-Aminoflunitrazepam panel


name: HEDIS 2009, 2010 Codes to identify anticonvulsant serum concentration monitoring tests - Phenytoin (MPM-E)


name: HEDIS 2009, 2010 Codes to identify exclusions (CHL-D)


name: Horizontal adduction.active range of motion


name: Influenza virus A H1 2009 pandemic RNA panel


name: MDS background information at admission form - version 2.0


name: MDS basic assessment tracking form - version 2.0


name: MDS quarterly assessment form - version 2.0


name: Outcome and assessment information set (OASIS) form - version B1


name: Avon Longitudinal Study of Parents and Children


name: Clinical.estimated from prior gest age assessment


name: National Council on Strenght and Fitness (NCFS)


name: Outcome and assessment information set (OASIS)-C


name: Saccharomyces cerevisiae leukotriene release


name: Confusion Assessment Method (CAM):-:Pt:^Patient:-:Observed.CAM.CARE


name: Inattention during 2D assessment period:Find:2D:^Patient:Ord:Observed.CAM.CARE


name: Disorganized thinking during 2D assessment period:Find:2D:^Patient:Ord:Observed.CAM.CARE


name: Altered level of consciousness &or alertness during 2D assessment period:Find:2D:^Patient:Ord:Observed.CAM.CARE


name: Psychomotor retardation during 2D assessment period:Find:2D:^Patient:Ord:Observed.CAM.CARE


name: Horizontal adduction.active range of motion:Angle:Pt:Shoulder.left:Qn


name: Body weight more or less than 5.5 pounds (2500 g)^at birth:Find:Pt:^Patient:Ord:Reported


name: Deprecated PhenX measure - child head circumference


name: Deprecated PhenX measure - hand dominance


name: Deprecated PhenX measure - hip circumference


name: Circumference.at maximal protrusion of gluteus muscles:Len:Pt:Pelvis:Qn


name: Deprecated PhenX measure - maximum adult height


name: Self-Reported Maximum Adult Height:-:Pt:^Patient:-


name: Body height^at age 25:Len:Pt:^Patient:Qn:Stated


name: Deprecated PhenX measure - maximum adult weight


name: Self-Reported Maximum Adult Weight:-:Pt:^Patient:-


name: Varicella zoster virus Ab.IgM^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus A Ab.IgG^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus A Ab.IgG^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus A Ab.IgM^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus A Ab.IgM^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus B Ab.IgM^1st specimen:ACnc:Pt:Ser:Qn:IA


name: Influenza virus B Ab.IgM^2nd specimen:ACnc:Pt:Ser:Qn:IA


name: Corticotropin^40M post XXX challenge:MCnc:Pt:Plas:Qn


name: Calcium.ionized^^adjusted to pH 7.4:MCnc:Pt:Ser/Plas:Qn:ISE


name: Deprecated Minimum Data Set - version 3.0


name: Federal OBRA reason for assessment:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Signs and symptoms of delirium (from CAM):-:Pt:^Patient:-:Observed.CAM.MDSv3


name: Inattention in last 7D:Find:7D:^Patient:Nom:CAM.CMS


name: Disorganized thinking in last 7D:Find:7D:^Patient:Ord:CAM.CMS


name: Altered level of consciousness in last 7D:Find:7D:^Patient:Ord:CAM.CMS


name: Psychomotor retardation in last 7D:Find:7D:^Patient:Ord:Observed.CAM.MDSv3


name: None of these signs of pain observed or documented in last 5D:Find:5D:^Patient:Ord:MDSv3


name: Fall one or more times in the last 2 to 6Mo prior to admission:Find:6Mo:^Patient:Ord:CMS Assessment


name: Guardian or legally authorized representative


name: Limb prosthesis normally used in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Indwelling catheter used in last 7D:Find:7D:^Patient:Ord:MDSv3


name: External catheter used in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Anemia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Atrial fibrillation and other dysrhythmias in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Coronary artery disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Deep venous thrombosis &or pulmonary embolus or pulmonary thrombo-embolism in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hypertension in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Peripheral Vascular Disease or Peripheral Arterial Disease:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Cirrhosis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Gastroesophageal reflux disease &or pressure injury in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Ulcerative colitis &or Crohn's disease &or inflammatory bowel disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Benign prostatic hyperplasia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Renal insufficiency or renal failure &or end-stage renal disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Pneumonia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Septicemia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Tuberculosis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Viral hepatitis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hyponatremia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hyperkalemia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hyperlipidemia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Thyroid disorder in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Arthritis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Osteoporosis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hip fracture in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Other fracture in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Alzheimer's disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Aphasia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Cerebral palsy in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Cerebrovascular accident &or transient ischemic attack &or stroke in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Non-Alzheimer's dementia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Hemiplegia &or hemiparesis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Paraplegia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Quadriplegia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Multiple sclerosis in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Parkinson's disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Seizure disorder or epilepsy:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Traumatic brain injury in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Protein or calorie malnutrition or at risk for malnutrition in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Anxiety disorder in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Depression other than bipolar in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Manic depression other than schizophrenia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Schizophrenia in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Post-traumatic stress disorder in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Asthma &or chronic obstructive lung disease or chronic lung disease in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Cataracts &or glaucoma or macular degeneration in last 7D:Find:7D:^Patient:Ord:MDSv3


name: None of the above active diagnoses in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Pain has made it hard to sleep:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Limited activities because of pain:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Rate pain severity using verbal descriptor scale:Find:RptPeriod:^Patient:Ord:CMS Assessment


name: Non-verbal sounds of pain in last 5D:Find:5D:^Patient:Ord:MDSv3


name: Vocal complaints of pain in last 5D:Find:5D:^Patient:Ord:MDSv3


name: Facial expressions of pain in last 5D:Find:5D:^Patient:Ord:MDSv3


name: Protective body movements or postures in last 5D:Find:5D:^Patient:Ord:MDSv3


name: Other disease diagnoses in last 7D:-:7D:^Patient:-:MDSv3


name: Application of nonsurgical dressings (with or without topical medications) other than to feet provided in last 7D:Find:7D:^Patient:Ord:MDSv3


name: Thyrotropin^3H post XXX challenge:ACnc:Pt:Ser/Plas:Qn


name: Latex recombinant (rHev b) 3 Ab.IgE:ACnc:Pt:Ser:Qn


name: Latex recombinant (rHev b) 5 Ab.IgE:ACnc:Pt:Ser:Qn


name: Latex recombinant (rHev b) 8 Ab.IgE:ACnc:Pt:Ser:Qn


name: Epstein Barr virus early Ab.IgM:ACnc:Pt:Ser:Qn:IA


name: Epstein Barr virus capsid Ab.IgM:ACnc:Pt:CSF:Qn:IA


name: 11-Deoxycorticosterone^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycorticosterone^2nd specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Thyroxine.free^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Thyroxine.free^40M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Thyroxine.free^1.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Thyroxine.free^20M post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Toxoplasma gondii Ab.IgG avidity:Ratio:Pt:Ser:Qn:IA


name: Toxoplasma gondii Ab.IgG avidity:PrThr:Pt:Ser/Plas:Ord:IA


name: 17-Hydroxyprogesterone^1D post dose dexamethasone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^1D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^2D post dose dexamethasone:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^2D post dose dexamethasone:SCnc:Pt:Ser/Plas:Qn


name: 18-Hydroxydeoxycorticosterone^30M post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 18-Hydroxydeoxycorticosterone^1H post dose corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Helianthus annuus seed Ab.IgG4:MCnc:Pt:Ser:Qn


name: Pregnancy weight gain.most recent:-:Pt:^Patient:-


name: Body weight more or less than 9.0 pounds (4100 g)^at birth:Find:Pt:^Patient:Ord:Reported


name: (Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgG4:MCnc:Pt:Ser:Qn


name: Triticum aestivum pollen Ab.IgG4:MCnc:Pt:Ser:Qn


name: EGFR gene exon 19 deletion:Arb:Pt:Bld/Tiss:Ord:Molgen


name: Measurement of platelet antibody (procedure)


name: Monitoring of blood pressure, temperature, pulse rate and respiratory rate


name: BANDAGE,DERMACEA 2IN X 4YD NONSTERILE KEN#441124


name: BANDAGE,DERMACEA 2IN X 4YD STERILE KEN#441108


name: BANDAGE,DERMACEA 3IN X 4YD NONSTERILE KEN#441123


name: BANDAGE,DERMACEA 4IN X 4YD NONSTERILE KEN#441122


name: BANDAGE,DERMACEA 4IN X 4YD STERILE KEN#441105


name: BANDAGE,DERMACEA 6IN X 4YD NONSTERILE KEN#441121


name: BANDAGE,DERMACEA 6IN X 4YD STERILE KEN#441109


name: BELT,SUPPORT 5IN X-LARGE NU-HOPE #6323-B


name: BELT,SUPPORT 6IN X-LARGE NU-HOPE #6603-A


name: BELT,SUPPORT 6IN XX-LARGE NU-HOPE #6434-A


name: BELT,SUPPORT 7IN XX-LARGE NU-HOPE #6444-F


name: CATHETER,FOLEY 2-WAY 12FR 5CC BARD#265712


name: CATHETER,FOLEY 2-WAY 14FR 5CC BARD#265714


name: CATHETER,FOLEY 2-WAY 16FR 5CC BARD#265716


name: CATHETER,FOLEY 2-WAY 18FR 5CC BARD#265718


name: CATHETER,FOLEY 2-WAY 20FR 5CC BARD#265720


name: CATHETER,FOLEY 2-WAY 22FR 5CC BARD#265722


name: CATHETER,FOLEY 2-WAY 24FR 5CC BARD#265724


name: CATHETER,FOLEY 2-WAY 26FR 5CC BARD#265726


name: CATHETER,FOLEY 2-WAY 28FR 5CC BARD#265728


name: CATHETER,INTERMITTENT VINYL 10FR M#DYND10721


name: CATHETER,INTERMITTENT VINYL 12FR M#DYND10722


name: CATHETER,INTERMITTENT VINYL 14FR M#DYND10723


name: CATHETER,INTERMITTENT VINYL 16FR M#DYND10724


name: CATHETER,INTERMITTENT VINYL 18FR M#DYND10725


name: CATHETER,INTERMITTENT,CLOSED SYSTEM 10FR COLOPLAST #1110


name: CATHETER,INTERMITTENT,CLOSED SYSTEM 12FR COLOPLAST #1112


name: CATHETER,INTERMITTENT,CLOSED SYSTEM 14FR COLOPLAST #1114


name: CATHETER,INTERMITTENT,CLOSED SYSTEM 16FR COLOPLAST #1116


name: CATHETER,INTERMITTENT,CLOSED SYSTEM 8FR COLOPLAST #1108


name: CATHETER,SELF-CATH 16FR COLOPLAST #50201


name: CATHETER,SELF-CATH COUDE 14FR COLOPLAST #50202


name: CATHETER,SELF-CATH COUDE 14FR COLOPLAST #50203


name: CATHETER,SELF-CATH COUDE 16FR COLOPLAST #50204


name: DRESSING,RESTORE CALCIUM ALGINATE AG 1IN X 12IN ROPE H#529969


name: DRESSING,RESTORE CALCIUM ALGINATE AG 2IN X 2IN H#529967


name: DRESSING,RESTORE CALCIUM ALGINATE AG 4IN X 4.75IN H#529968


name: {1 (45000 MG Benzoyl Peroxide 55 MG/ML Topical Cream [NeoBenz Micro]) / 7 (500 MG Benzoyl Peroxide 55 MG/ML Prefilled Applicator [NeoBenz Micro SD]) } Pack [NeoBenz Micro Cream Plus Pack]


name: {1 (180000 MG Benzoyl Peroxide 70 MG/ML Medicated Liquid Soap [NeoBenz Micro Wash]) / 7 (500 MG Benzoyl Peroxide 55 MG/ML Prefilled Applicator [NeoBenz Micro SD]) } Pack [NeoBenz Micro Wash Plus Pack]


name: dihydrocodeine / phenylephrine / pyrilamine


name: {30 (ascorbic acid 120 MG / calcium citrate 125 MG / cholecalciferol 400 UNT / folic acid 1 MG / iron carbonyl 20 MG / pyridoxine hydrochloride 25 MG Oral Tablet) / 10 (pyridoxine hydrochloride 25 MG Oral Tablet) } Pack [CitraNatal B-Calm Kit]


name: {5 (20 ML ifosfamide 50 MG/ML Injection) / 3 (mesna 100 MG/ML Injectable Solution) } Pack


name: generic drug products begining with the letter H


name: {1 (225 ML) (ammonium lactate 120 MG/ML Topical Lotion) / 1 (50 ML) (halobetasol propionate 0.0005 MG/MG Topical Ointment) } Pack


name: lamotrigine kit (For Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Rifampin and Not Taking Valproate) includes Green & Orange Pack


name: {4 (risedronate sodium 35 MG Oral Tablet) } Pack


name: Estimated date of delivery:Find:Pt:^Patient:Nar


name: Time contractions became regular:TmStp:Pt:^Patient:Qn


name: Deprecated Operative note - surgical drains (narrative)


name: Candida albicans Ab.IgA & IgG & IgM panel:-:Pt:Ser:Qn


name: brompheniramine maleate, pseudoephedrine hydrochloride drug combination


name: clindamycin phosphate benzoyl peroxide combination


name: pancreatic extract, povidone drug combination


name: aluminum hydroxide, dimethylpolsiloxane, magnesium carbonate, magesium hydroxide drug combination


name: aluminum hydroxide, benzocaine, magnesium hydroxide, sorbitol drug combination


name: aluminum hydroxide, magnesium hydroxide, sorbitol drug combination


name: aluminum hydroxide, benzocaine, magnesium hydroxide drug combination


name: aluminum glycinate, magnesium hydroxide, drug combination


name: Research Support, American Recovery and Reinvestment Act


name: Labor and Delivery record panel:-:Pt:^Patient:-


name: Transmyocardial Laser Revascularization (procedure)


name: MEBROFENIN 45 mg in 10 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION


name: CATHETER,EXTERNAL GOLDEN DRAIN MED #A2000M


name: CATHETER,FOLEY 2-WAY 14FR 10CC ROCHESTER #19214


name: CATHETER,FOLEY 2-WAY 14FR 10CC ROCHESTER #82514


name: CATHETER,FOLEY 2-WAY 16FR 10CC ROCHESTER #19216


name: CATHETER,FOLEY 2-WAY 16FR 10CC ROCHESTER #82516


name: CATHETER,FOLEY 2-WAY 18FR 10CC ROCHESTER #82518


name: CATHETER,FOLEY 2-WAY 20FR 10CC ROCHESTER #19220


name: CATHETER,FOLEY 2-WAY 20FR 10CC ROCHESTER #82520


name: CATHETER,FOLEY 2-WAY 22FR 10CC ROCHESTER #19222


name: CATHETER,FOLEY 2-WAY 22FR 10CC ROCHESTER #82522


name: CATHETER,FOLEY 2-WAY 24FR 10CC ROCHESTER #19224


name: CATHETER,FOLEY 2-WAY 24FR 10CC ROCHESTER #82524


name: CATHETER,FOLEY SILICONE 2-WAY 12FR 5CC KENDALL #3125


name: GLOVE LATEX SMALL CHEMO 18 MIL KEN#CT1091-1 (PAIR)


name: GLOVE LATEX MEDIUM CHEMO 18 MIL KEN#CT1092-1 (PAIR)


name: CATHETER,INTERMITTENT,MAGIC3 FEMALE 14FR ROCHESTER #51314


name: CATHETER,INTERMITTENT,MAGIC3 FEMALE 12FR ROCHESTER #51312


name: CATHETER,INTERMITTENT,MAGIC3 16FR ROCHESTER #53316


name: CATHETER,INTERMITTENT,MAGIC3 14FR ROCHESTER #53314


name: CATHETER,INTERMITTENT,MAGIC3 12FR ROCHESTER #53312


name: CATHETER,FOLEY SILICONE 2-WAY 30FR 5CC KENDALL #3577


name: CATHETER,FOLEY SILICONE 2-WAY 26FR 5CC KENDALL #3573


name: CATHETER,FOLEY 2-WAY 18FR 10CC ROCHESTER #19218


name: CATHETER,FOLEY SILICONE 2-WAY 14FR 30CC KENDALL #4149


name: CATHETER,FOLEY SILICONE 2-WAY 14FR 5CC KENDALL #3558


name: CATHETER,FOLEY SILICONE 2-WAY 16FR 30CC KENDALL #3601


name: CATHETER,FOLEY SILICONE 2-WAY 16FR 5CC KENDALL #3560


name: CATHETER,FOLEY SILICONE 2-WAY 18FR 30CC KENDALL #0187


name: CATHETER,FOLEY SILICONE 2-WAY 18FR 30CC KENDALL #3607


name: CATHETER,FOLEY SILICONE 2-WAY 18FR 5CC KENDALL #3563


name: CATHETER,FOLEY SILICONE 2-WAY 20FR 30CC KENDALL #0203


name: CATHETER,FOLEY SILICONE 2-WAY 20FR 30CC KENDALL #3611


name: CATHETER,FOLEY SILICONE 2-WAY 20FR 5CC KENDALL #3565


name: CATHETER,FOLEY SILICONE 2-WAY 22FR 30CC KENDALL #0229


name: CATHETER,FOLEY SILICONE 2-WAY 22FR 30CC KENDALL #3614


name: CATHETER,FOLEY SILICONE 2-WAY 22FR 5CC KENDALL #3567


name: CATHETER,FOLEY SILICONE 2-WAY 26FR 30CC KENDALL #3619


name: CATHETER,FOLEY SILICONE 2-WAY 28FR 30CC KENDALL #3623


name: CATHETER,FOLEY SILICONE 2-WAY 28FR 5CC KENDALL #3575


name: CATHETER,FOLEY SILICONE 2-WAY 30FR 30CC KENDALL #3631


name: GLOVE LATEX LARGE CHEMO 18 MIL KEN#CT1093-1 (PAIR)


name: VALVE PORT POSITIVE BOLUS NEEDLE FREE ALARIS #3000E


name: CATHETER,FOLEY SILICONE 2-WAY 24FR 30CC KENDALL #3618


name: CATHETER,FOLEY SILICONE 2-WAY 24FR 5CC KENDALL #3570


name: CATHETER,FOLEY SILICONE 2-WAY 26FR 30CC KENDALL #0260


name: KRT16, 23-BP DEL, NT1244 AND 1-BP DEL, 1270G


name: XPC, 3-BP INS, GGT, CODON 580 AND LYS822GLN


name: Narcotic Cough/Cold Preparations Oral syrup


name: mesenchymal cell migration involved in limb bud formation


name: regulation of skeletal muscle tissue regeneration


name: inhibition of neuroepithelial cell differentiation


name: thyroid hormone receptor signaling pathway


name: regulation of skeletal muscle tissue development


name: production of molecular mediator involved in acute inflammatory response


name: vibrational conductance of sound to the inner ear


name: positive regulation of sperm motility involved in capacitation


name: positive regulation of epithelial cell proliferation involved in lung morphogenesis


name: smoothened signaling pathway involved in lung development


name: epidermal growth factor receptor signaling pathway involved in lung development


name: multicellular organismal-level iron ion homeostasis


name: fibroblast growth factor receptor signaling pathway involved in mammary gland specification


name: positive regulation of mammary placode formation by mesenchymal-epithelial signaling


name: positive regulation of lactation by mesenchymal-epithelial cell signaling


name: regulation of epithelial cell proliferation involved in mammary gland bud elongation


name: negative regulation of prostatic bud formation


name: regulation of branching involved in prostate gland morphogenesis


name: regulation of morphogenesis of a branching structure


name: regulation of branching involved in salivary gland morphogenesis


name: regulation of response to cytokine stimulus


name: positive regulation of response to cytokine stimulus


name: negative regulation of response to cytokine stimulus


name: regulation of branching involved in mammary gland duct morphogenesis


name: mesenchymal smoothened signaling pathway involved in prostate gland development


name: positive regulation of posterior neural plate formation by fibroblast growth factor receptor signaling pathway


name: fibroblast growth factor receptor signaling pathway involved in neural plate anterior/posterior pattern formation


name: smoothened signaling pathway involved in dorsal/ventral neural tube patterning


name: vascular endothelial growth factor receptor signaling pathway involved in lymphatic endothelial cell fate commitment


name: Notch signaling pathway involved in arterial endothelial cell fate commitment


name: positive regulation of floral organ abscission


name: negative regulation of floral organ abscission


name: regulation of floral organ abscission by signal transduction


name: positive regulation of cartilage development


name: negative regulation of cartilage development


name: negative regulation of vascular wound healing


name: regulation of branching involved in lung morphogenesis


name: positive regulation of branching involved in lung morphogenesis


name: negative regulation of branching involved in lung morphogenesis


name: peptidoglycan recognition protein signaling pathway


name: regulation of peptidoglycan recognition protein signaling pathway


name: positive regulation of peptidoglycan recognition protein signaling pathway


name: negative regulation of peptidoglycan recognition protein signaling pathway


name: regulation of nematode larval development


name: positive regulation of nematode larval development


name: negative regulation of nematode larval development


name: positive regulation of dauer larval development


name: negative regulation of dauer larval development


name: positive regulation of neural retina development


name: negative regulation of neural retina development


name: regulation of neuron projection regeneration


name: negative regulation of neuron projection regeneration


name: positive regulation of neuron projection regeneration


name: respiratory burst involved in defense response


name: immune response-regulating signaling pathway


name: Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation


name: smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation


name: Wnt signaling pathway involved in heart development


name: regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis


name: regulation of growth plate cartilage chondrocyte proliferation


name: growth plate cartilage axis specification


name: regulation of cytoskeleton polarization involved in growth plate cartilage chondrocyte division


name: negative regulation of conidiophore stalk development


name: positive regulation of conidiophore stalk development


name: semaphorin-plexin signaling pathway involved in outflow tract morphogenesis


name: hydrogen peroxide mediated signaling pathway


name: organism emergence from protective structure


name: regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis


name: negative regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis


name: positive regulation of ureteric bud formation


name: positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis


name: negative regulation of response to water deprivation


name: positive regulation of leaflet formation by auxin mediated signaling pathway


name: positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway


name: regulation of establishment of planar polarity


name: regulation of pancreatic juice secretion


name: positive regulation of glomerulus development


name: negative regulation of glomerulus development


name: regulation of radial pattern specification


name: fibroblast growth factor receptor signaling pathway involved in somitogenesis


name: Wnt signaling pathway involved in somitogenesis


name: SUCTION TUBE ATTACHMENT DEVICE MEDLINE #DYND50140


name: TUBING,EXTENSION 15IN W/CONNECTOR RUSCH#A3605S


name: CATHETER,SUCTION 14-16FR W/VENT BARD #0109150


name: {180 (acamprosate calcium 333 MG Delayed Release Oral Tablet [Campral]) } Pack [Campral Dose Pak]


name: {1 (acetaminophen 33.3 MG/ML / dextromethorphan hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution) / 1 (acetaminophen 33.3 MG/ML / dextromethorphan hydrobromide 1 MG/ML Oral Solution) } Pack


name: Ointment with Applicator Drug Delivery System


name: Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine


name: Date of myocardial infarction:Date:Pt:^Patient:Qn


name: Stress Cardiac Magnetic Resonance Imaging


name: Pre-Test Probability of Coronary Artery Disease


name: Left Ventricle Size, End-Diastole, Quantitative


name: Left Ventricle Size, End-Systole, Quantitative


name: Cytokeratin 5/6 Immunohistochemical Expression


name: Last Observation Carried Forward Imputation Technique


name: Worst Observation Carried Forward Imputation Technique


name: Screening Observation Carried Forward Imputation Technique


name: Baseline Observation Carried Forward Imputation Technique


name: Mean of Other Group Imputation Technique


name: Penultimate Observation Carried Forward Imputation Technique


name: Worst Observed Value in a Group Imputation Technique


name: Mean Observed Value in a Group Imputation Technique


name: CDISC ADaM Date Imputation Flag Terminology


name: CDISC ADaM Time Imputation Flag Terminology


name: Brazelton Neonatal Behavioral Assessment Scale


name: Third National Health and Nutrition Examination Survey


name: Reg upon Act Normal T-cell Exprd Secrtd Measurement


name: Mid-Molecule Parathyroid Hormone Measurement


name: N-Terminal Parathyroid Hormone Measurement


name: Anti-Saccharomyces cerevisiae Antibody Measurement


name: Aspartate Aminotransferase Antigen Measurement


name: Islet Neogenesis Associated Protein Antibody Measurement


name: Plasminogen Activator Inhibitor-1 Antigen Measurement


name: Thyroid Antithyroglobulin Antibody Measurement


name: Tissue Plasminogen Activator Antigen Measurement


name: Brain-Derived Neurotrophic Factor Measurement


name: Epithelial Neutrophil-Activating Peptide 78 measurement


name: Extracell Newly Ident RAGE Bind Protein measurement


name: Fatty Acid Binding Protein 1 Measurement


name: Fibroblast Growth Factor Basic Form Measurement


name: Glutamic Acid Decarboxylase 1 Measurement


name: Glutamic Acid Decarboxylase 2 Measurement


name: Glutamic Acid Decarboxylase 2 Antibody Measurement


name: Granulocyte Colony Stimulating Factor Measurement


name: Granulocyte Macrophage Colony Stimulating Factor Measurement


name: Macrophage Inflammatory Protein 1 Alpha measurement


name: Macrophage Inflammatory Protein 1 Beta measurement


name: Monocyte Chemotactic Protein 1 Measurement


name: Polymorphonuclear Neutrophil Elastase Measurement


name: Polymorphonuclear Pancreatic Elastase Measurement


name: Plasminogen Activator Inhibitor-1 Measurement


name: ProB-Type Natriuretic Peptide Measurement


name: Procollagen Type I Carboxy Terminal Peptide Measurement


name: Tissue Inhibitor of Metalloproteinase 1 Measurement


name: Type I Collagen C-Telopeptide Measurement


name: Type I Collagen N-Telopeptide Measurement


name: Type II Collagen C-Telopeptide Measurement


name: Type II Collagen N-Telopeptide Measurement


name: Vascular Cell Adhesion Molecule 1 Measurement


name: Vascular Epithelial Growth Factor Measurement


name: Segmented Neutrophil to Leukocyte Ratio Measurement


name: Nucleated Erythrocyte to Leukocyte Ratio Measurement


name: Healthcare Information Technology Standards Panel


name: North American Association of Central Cancer Registries


name: Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine


name: Between 6 Months and Less Than 12 Months


name: Both Safety and Lack of Expected Effectiveness


name: Clinical Study Safety Issue and Lack of Effectiveness


name: Manufacturing Product Defect Manufacturing Defect Both Safety And LOEE


name: Manufacturing Product Defect Manufacturing Defect LOEE


name: Manufacturing Product Defect Manufacturing Defect Safety


name: Manufacturing Product Defect Manufacturing Defect With No Adverse Events


name: Division of Blood Diseases and Resources


name: Division of Epidemiology and Clinical Applications


name: National Institute on Minority Health and Health Disparities


name: Offices of Research Facilities Development and Operations


name: Office of Logistics and Acquisition Operations


name: Center for Biologics Evaluation and Research


name: Center for Devices and Radiological Health


name: Ionic Silver-Impregnated Sodium Carboxymethylcellulose Antimicrobial Dressing


name: Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621


name: International Union of Pure and Applied Chemistry


name: S-100 Immunohistochemistry Staining Method


name: CDISC CDASH Substance Use Never/Current/Former Classification Terminology


name: Adverse Event Action Taken with Study Treatment


name: Concomitant Medication Active Ingredient


name: Drug Accountability Record Categorization


name: Electrocardiogram Results Clinically Significant Occurrence


name: Laboratory Test Result Clinically Significant


name: Physical Examination Clinically Significant


name: Exposure Total Volume Administration Unit


name: Laboratory Test Reference Range Upper Limit Original Unit


name: Adverse Event Sponsor Defined Identifier


name: Concomitant Medication Use Sponsor Defined Identifier


name: Protocol Deviation Sponsor Defined Identifier


name: Medical History Sponsor Defined Identifier


name: Physical Examination Sponsor Defined Identifier


name: Laboratory Test Reference Range Indicator


name: Laboratory Test Reference Range Lower Limit Original Unit


name: Laboratory Test Reference Range for Character Results Standard Unit


name: Concomitant Medication Adverse Event Number


name: Concomitant Medication Medical History Number


name: Drug Accountability Assessment Original Result


name: Drug Accountability Assessment Result Original Units


name: Electrocardiogram Original Result Unit of Measure


name: Other Actions taken in Response to Adverse Event


name: Concomitant Medication Route of Administration


name: Protocol Deviation Dictionary Derived Term


name: Drug Accountability Record Subcategorization


name: Concomitant Medication Administration Dose


name: Drug Accountability Treatment Dispensation Date


name: Drug Accountability Treatment Return Date


name: Adverse Event End Relative to Reference Period


name: Concomitant Medication Use End Date Time


name: Concomitant Medication Use End Relative to Reference Period


name: Concomitant Medication Modified Reported Term


name: Concomitant Medication Reason Not Collected


name: Concomitant Medication Use Completion Status


name: Concomitant Medication Use Start Date Time


name: Concomitant Medication Use Start Relative to Reference Period


name: Drug Accountability Assessment Test Code


name: Electrocardiogram Reference Range Indicator


name: Electrocardiogram Character Result in Standard Format


name: Electrocardiogram Numeric Result in Standard Unit


name: Electrocardiogram Planned Time Point Number


name: Inclusion Exclusion Criterion Collection Date Time


name: Inclusion Exclusion Criterion Data Collection Day


name: Inclusion Exclusion Criterion Original Result


name: Inclusion Exclusion Criterion Subcategory


name: Inclusion Exclusion Criterion Sequence Number


name: Inclusion Exclusion Criterion Sponsor Defined Identifier


name: Inclusion Exclusion Criterion Character Result in Standard Format


name: Laboratory Test Sponsor Defined Identifier


name: Laboratory Test Reference Range Upper Limit Standard Unit


name: Laboratory Test Reference Range Lower Limit Standard Unit


name: Laboratory Test Character Result in Standard Unit


name: Laboratory Test Numeric Result in Standard Unit


name: Laboratory Test Planned Time Point Number


name: Medical History Data Collection Date Time


name: Medical History End Relative to Reference Period


name: Physical Examination Collection Date Time


name: Concomitant Medication Dictionary Derived Term


name: Physical Examination Data Collection Day


name: Physical Examination Modified Reported Term


name: Physical Examination Original Result Unit


name: Physical Examination Character Result in Standard Unit


name: Physical Examination Numeric Result in Standard Unit


name: Physical Examination Result Standard Unit


name: Questionnaire Sponsor Defined Identifier


name: Questionnaire Character Result in Standard Unit


name: Questionnaire Numeric Result in Standard Unit


name: Subject Characteristics Data Collection Date Time


name: Subject Characteristics Data Collection Day


name: Subject Characteristics Group Identifier


name: Subject Characteristics Original Result Unit


name: Subject Characteristics Sponsor Defined Identifier


name: Subject Characteristics Character Result in Standard Unit


name: Subject Characteristics Numeric Result in Standard Unit


name: Subject Characteristics Result Standard Unit


name: Substance Usage Dictionary Derived Substance Term


name: Substance Use End Relative to Reference Period


name: Substance Use Sponsor Defined Identifier


name: Substance Use Start Relative to Reference Period


name: Trial Inclusion Exclusion Criteria Version


name: Vital Signs Character Result in Standard Unit


name: Vital Signs Numeric Result in Standard Unit


name: Biomarker Imaging Quality of Life Studies Funding Program


name: International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes


name: Nonphosphorylated Tau Protein Measurement


name: Human Trefoil Factor 1-Secreting Lactococcus lactis AG013


name: Disabilities of the Arm Shoulder and Hand Outcome Measure


name: COX-2 Immunohistochemical Expression Analysis


name: Pediatric Oncology Group Neuroblastoma Staging System


name: Findings About Events or Interventions Domain


name: CDISC SDTM Pharmacokinetic Parameter Long Name Terminology


name: CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology


name: CDISC SDTM Microbiology Susceptibility Testing Result Category Terminology


name: Volume of Distribution of Absorbed Fraction


name: Antimicrobial Combination Testing Method


name: Area Under the Curve From Dosing to Last Concentration


name: Area Under the Curve Over Dosing Interval


name: Area Under the First Moment Curve From Dosing to Last Concentration


name: Area Under the First Moment Curve Over Dosing Interval


name: Concentration Variability Between Dose Time and Tau


name: Hour Squared Times Microgram per Milliliter


name: Hour Squared Times Micromole per Milliliter


name: Hour Squared Times Milligram per Milliliter


name: Hour Squared Times Millimole per Milliliter


name: Hour Squared Times Nanogram per Milliliter


name: Hour Squared Times Picogram per Milliliter


name: Hour Squared Times Picomole per Milliliter


name: Hour Times Microgram per Milliliter per Milligram


name: Hour Times Milligram per Liter per Milligram


name: Hour Times Nanogram per Milliliter per Gram


name: Hour Times Nanogram per Milliliter per Kilogram


name: Hour Times Nanogram per Milliliter per Milligram


name: Hour Times Nanogram per Milliliter per Milligram per Kilogram


name: Hour Times Nanogram per Milliliter per Milligram per Meter Squared


name: Hour Times Nanogram per Milliliter Times Kilogram


name: Hour Times Nanomole per Liter per Micromole


name: Hour Times Nanomole per Milliliter per Milligram


name: Hour Times Picogram per Milliliter per Kilogram


name: Hour Times Picogram per Milliliter per Microgram


name: Hour Times Picomole per Liter per Microgram


name: Hour Times Picomole per Milliliter per Milligram


name: Observed Area Under the Curve Infinity by Dose


name: Observed Area Under the Curve Percent Back Extrapolation


name: Observed Area Under the Curve Percent Extrapolation


name: Observed Area Under the First Moment Curve Infinity


name: Observed Area Under the First Moment Curve Percent Extrapolation


name: Observed Steady State Volume of Distribution


name: Observed Steady State Volume of Distribution at Terminal Phase


name: Observed Total Body Clearance by Fraction of Dose Absorbed


name: Observed Volume of Distribution of Absorbed Fraction


name: Predicted Area Under the Curve Infinity by Dose


name: Predicted Area Under the Curve Percent Back Extrapolation


name: Predicted Area Under the Curve Percent Extrapolation


name: Predicted Area Under the First Moment Curve Infinity


name: Predicted Area Under the First Moment Curve Percent Extrapolation


name: Predicted Steady State Volume of Distribution


name: Predicted Steady State Volume of Distribution at Terminal Phase


name: Predicted Total Body Clearance by Fraction of Dose Absorbed


name: Predicted Volume of Distribution of Absorbed Fraction


name: Steady State Total Body Clearance by Fraction of Dose Absorbed


name: CDISC SDTM Pharmacokinetic Parameter Short Name Terminology


name: Mycobacterial Interspersed Repetitive Unit Typing


name: Wechsler Preschool and Primary Scale of Intelligence


name: p16 Immunohistochemical Expression Analysis


name: In Situ Hybridization Analysis of HPV 16 DNA Sequences


name: International Classification of Diseases for Oncology, Third Edition


name: CDISC SDTM Common Terminology Criteria for Adverse Event Grade Terminology Version 4.0


name: Cognitive Abilities Screening Instrument


name: International Classification of Diseases for Oncology, Second Edition


name: International Classification of Diseases, 10th Edition, Clinical Modification


name: Special screening for malignant neoplasms of ovary


name: supervision of high risk pregnancy (treatment)


name: {28 (norethindrone 0.35 MG Oral Tablet) } Pack [Heather 28 Day]


name: IRRIGATION KIT W/BULB SYRINGE #DYND20102


name: TRACH VALVE HOUSING,ADHESIVE BLOM-SINGER BE6072


name: UNDERPAD,BED ULTRASORB 23IN X 36IN #MSC282100


name: {5 (dienogest 2 MG / estradiol valerate 2 MG Oral Tablet) / 17 (dienogest 3 MG / estradiol valerate 2 MG Oral Tablet) / 2 (estradiol valerate 1 MG Oral Tablet) / 2 (estradiol valerate 3 MG Oral Tablet) / 2 (inert ingredients 1 MG Oral Tablet) } Pack


name: {5 (dienogest 2 MG / estradiol valerate 2 MG Oral Tablet) / 17 (dienogest 3 MG / estradiol valerate 2 MG Oral Tablet) / 2 (estradiol valerate 1 MG Oral Tablet) / 2 (estradiol valerate 3 MG Oral Tablet) / 2 (inert ingredients 1 MG Oral Tablet) } Pack [Natazia 28 Day]


name: IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative KIT


name: {1 (240 ML) (ammonium lactate 120 MG/ML Topical Lotion) / 1 (50000 MG) (halobetasol propionate 0.0005 MG/MG Topical Ointment) } Pack [Halonate Pac]


name: Peroxisome Proliferator Receptor alpha Agonist


name: STANNOUS CHLORIDE 0.05 mg in 9.5 mg INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [RBC REACTION VIAL]


name: {28 (estradiol 1 MG / norethindrone acetate 0.5 MG Oral Tablet) } Pack [Mimvey]


name: Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor


name: Copper-containing Intrauterine Device [EPC]


name: Aromatic Amino Acid Decarboxylation Inhibitor


name: Glucosylceramide Synthase Inhibitor [EPC]


name: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme


name: Hydrolytic Lysosomal Glycogen-specific Enzyme


name: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme


name: Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme


name: 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC]


name: Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor


name: Herpes Simplex Virus Pyrophosphate Analog DNA Polymerase Inhibitor


name: Human CTLA-4 and Fc-IgG1 Recombinant Fusion Protein


name: Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor


name: Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor


name: Iodinated Contrast Agent for Radiographic Imaging


name: Dietary Cholesterol Absorption Inhibitor [EPC]


name: Epidermal Growth Factor Receptor Antagonist [EPC]


name: Dihydrofolate Reductase Inhibitor Antimalarial


name: Dihydrofolate Reductase Inhibitor Antimicrobial


name: Peroxisome Proliferator Receptor gamma Agonist [EPC]


name: Serotonin-1b and Serotonin-1d Receptor Agonist


name: Recombinant Human Deoxyribonuclease 1 [EPC]


name: Monoamine Oxidase Type B Inhibitor [EPC]


name: Norepinephrine Reuptake Inhibitor Anorectic


name: Mucocutaneous Epithelial Cell Growth Factor


name: alpha-Adrenergic and beta-Adrenergic Agonist [EPC]


name: {24 (drospirenone 3 MG / ethinyl estradiol 0.02 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Gianvi 28-Day]


name: CATHETER,FOLEY 2-WAY SILICONE 12FR 5CC KENDALL #2712


name: CATHETER,FOLEY 2-WAY SILICONE 14FR 5CC KENDALL #2714


name: CATHETER,FOLEY 2-WAY SILICONE 16FR 5CC KENDALL #2716


name: CATHETER,FOLEY 2-WAY SILICONE 18FR 5CC KENDALL #2718


name: CATHETER,FOLEY 2-WAY SILICONE 20FR 5CC KENDALL #2720


name: CATHETER,FOLEY 2-WAY SILICONE 30FR 5CC KENDALL #2730


name: UNDERPAD,BED ULTRASORB 31IN X 36IN MEDLINE #3136


name: CATHETER,FOLEY 2-WAY SILICONE 22FR 5CC KENDALL #2722


name: CATHETER,FOLEY 2-WAY SILICONE 24FR 5CC KENDALL #2724


name: CATHETER,FOLEY 2-WAY SILICONE 26FR 5CC KENDALL #2726


name: CATHETER,FOLEY 2-WAY SILICONE 28FR 5CC KENDALL #2728


name: GLOVE NITRILE MEDIUM PWDR-FREE NONSTERILE TEXTURED


name: GLOVE NITRILE SMALL PWDR-FREE NONSTERILE TEXTURED


name: GLOVE NITRILE X-LARGE PWDR-FREE NONSTERILE TEXTURED


name: GLOVE NITRILE LARGE PWDR-FREE NONSTERILE TEXTURED


name: {30 (calcium ascorbate 25 MG / calcium carbonate 400 MG / cholecalciferol 200 UNT / folic acid 2 MG / pyridoxine hydrochloride 25 MG Oral Tablet) / 30 (calcium ascorbate 25 MG / calcium carbonate 600 MG / cholecalciferol 600 UNT / folic acid 0.5 MG / pyridoxine hydrochloride 12.5 MG Oral Tablet) / 60 (linoleic acid 10 MG / omega-3 acid ethyl esters (USP) 650 MG / vitamin E 50 UNT Oral Capsule) } Pack


name: {7 (24 HR memantine hydrochloride 14 MG Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 21 MG Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 28 MG Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 7 MG Extended Release Oral Capsule) } Pack


name: {7 (24 HR memantine hydrochloride 14 MG Extended Release Oral Capsule [Namenda]) / 7 (24 HR memantine hydrochloride 21 MG Extended Release Oral Capsule [Namenda]) / 7 (24 HR memantine hydrochloride 28 MG Extended Release Oral Capsule [Namenda]) / 7 (24 HR memantine hydrochloride 7 MG Extended Release Oral Capsule [Namenda]) } Pack [Namenda 28 Titration Pack]


name: Supervision of high risk pregnancy due to social problems


name: {1 (225 ML) (ammonium lactate 120 MG/ML Topical Lotion [Lac-Hydrin]) / 1 (50 ML) (halobetasol propionate 0.5 MG/ML Topical Cream [Ultravate]) } Pack [Ultravate Pac Cream]


name: Residual cancer burden index (observable entity)